News

Eden Research plc is an LSE AIM listed company and the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

Based on plant-derived active ingredients, Mevalone ® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden’s addressable market globally.

Cedroz ™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden’s commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Placing, Subscription and Retail Offer

On 2^nd February 2026, the company announced that it has raised approximately £3.1 million through a firm placing and subscription of 76,250,000 new Ordinary Shares and has conditionally raised approximately £7.6 million by way of a placing of 190,000,000 new Ordinary Shares. The Firm Capital Raising and the Conditional Placing will be at the issue price of 4.0 pence per Ordinary Share to certain institutional and other investors.

On 5^th February 2026, the company further announced that the Retail Offer launched on 2^nd   February 2026 had closed, raising further gross proceeds of approximately £0.2 million. Subject to the Retail Offer becoming unconditional, a total of 3,760,473 Retail Offer Shares will be issued at a price of 4.0 pence each.

The Perivan shareholder communications team was delighted to work with Cavendish Capital Markets who acted as Nominated Adviser and Joint Bookrunner on the production of the shareholder documentation which was successfully produced and posted to qualifying shareholders on 2^nd February 2026.

Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and are a market leader in the production of documentation relating to corporate finance transactions.